Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type  2 Diabetes: Propensity Score Matched Analysis

ConclusionsIn patients with T2D inadequately controlled on basal insulin, iGlarLixi offers an effective alternative to BB regimen for reducing HbA1c, without increased risk of hypoglycemia and weight gain.Trial RegistrationClinicalTrials.gov: NCT02058160 (LixiLan-L trial); NCT01768559 (GetGoal Duo-2 trial).Plain Language SummaryPlain language summary available for this article.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research